These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 33981518)

  • 21. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
    Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
    N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
    Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
    JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
    Jones BE; Brown-Augsburger PL; Corbett KS; Westendorf K; Davies J; Cujec TP; Wiethoff CM; Blackbourne JL; Heinz BA; Foster D; Higgs RE; Balasubramaniam D; Wang L; Zhang Y; Yang ES; Bidshahri R; Kraft L; Hwang Y; Žentelis S; Jepson KR; Goya R; Smith MA; Collins DW; Hinshaw SJ; Tycho SA; Pellacani D; Xiang P; Muthuraman K; Sobhanifar S; Piper MH; Triana FJ; Hendle J; Pustilnik A; Adams AC; Berens SJ; Baric RS; Martinez DR; Cross RW; Geisbert TW; Borisevich V; Abiona O; Belli HM; de Vries M; Mohamed A; Dittmann M; Samanovic MI; Mulligan MJ; Goldsmith JA; Hsieh CL; Johnson NV; Wrapp D; McLellan JS; Barnhart BC; Graham BS; Mascola JR; Hansen CL; Falconer E
    Sci Transl Med; 2021 May; 13(593):. PubMed ID: 33820835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.
    Dale AP; Hudson MJ; Armenta D; Friebus H; Ellingson KD; Davis K; Cullen T; Brady S; Komatsu KK; Stone ND; Uyeki TM; Slifka KJ; Pérez-Vélez CM; Keaton AA
    J Am Geriatr Soc; 2022 Apr; 70(4):960-967. PubMed ID: 35141874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
    Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
    Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real World Utilization of Bamlanivimab at a Rural Community Hospital.
    Leavitt R; Ash J; Hasenbalg P; Santarelli A; Dietrich T; Schritter S; Wells J; Dawson A; Ashurst J
    Cureus; 2021 Nov; 13(11):e19747. PubMed ID: 34938624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019.
    Abbas M; Farhat N; Hammoud Z; Dickey C; Shuayto A; Chen NW; Hsaiky LM; Sims M; Sengstock D; Schramski J; Shamoon Z
    J Intensive Care Med; 2023 Jun; 38(6):511-518. PubMed ID: 36775970
    [No Abstract]   [Full Text] [Related]  

  • 31. Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents.
    Alexander PE; Armstrong R; Fareed G; Lotus J; Oskoui R; Prodromos C; Risch HA; Tenenbaum HC; Wax CM; Dara P; McCullough PA; Gill KK
    Med Hypotheses; 2021 Aug; 153():110622. PubMed ID: 34130113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
    Ganesh R; Pawlowski CF; O'Horo JC; Arndt LL; Arndt RF; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan PJ; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
    J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
    Tuccori M; Convertino I; Ferraro S; Valdiserra G; Cappello E; Fini E; Focosi D
    Expert Opin Drug Discov; 2021 Dec; 16(12):1403-1414. PubMed ID: 34304682
    [No Abstract]   [Full Text] [Related]  

  • 34. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
    Monday LM; Brar I; Alangaden G; Ramesh MS
    J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community.
    Iqbal L; Terlau TJ; Hernandez A; Woods K
    Cureus; 2021 Jul; 13(7):e16477. PubMed ID: 34430093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort.
    Goldin S; Adler L; Azuri J; Mendel L; Haviv S; Maimon N
    Gerontology; 2022; 68(12):1350-1357. PubMed ID: 35134810
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.